Report Id: SNS/HC/2480 | July 2022 | Region: Global | 133 Pages
Report Scope & Overview:
Geographic Atrophy (GA) Market expected to grow at a CAGR of 7.2% over the forecast period 2023-2030. Geographic atrophy, a severe form of age-related macular degeneration (AMD), causes the macula to continuously deteriorate over time. This syndrome is characterised by extensive atrophy of the choriocapillaris, outer retinal tissue, and retinal pigment epithelium. Typically, it begins in the perifoveal area and moves into the fovea over time, resulting in central scotomas and irreversible vision loss.
Increasing number of seniors
Geographic atrophy is becoming more common in every country.
Pharmaceutical and biopharmaceutical companies are investing more money in research and development.
Medicines used to treat geographic atrophy are subject to strict government controls.
Geographic atrophy and other ocular illnesses are not widely known in less developed nations.
The creation of novel treatments for geographic atrophy
Utilizing gene therapy to cure geographic atrophy is an example of technology.
Players in the geographic atrophy industry may have difficulties because to the rigorous rules being enforced by governments around the world.
IMPACT OF COVID-19
With the COVID-19 outbreak and the significant financial losses suffered by several industries globally, including the healthcare sector, the year 2020 took an unexpected turn. The COVID-19 epidemic made things worse by impacting, among other areas, the healthcare sector and upsetting supply networks. The pandemic has hurt the geographic atrophy market since the vendors have had to close their manufacturing facilities or keep them operating at considerably lower production levels in order to stop the new coronavirus from spreading.
On the plus side, the market for geographic atrophy might experience significant growth over the next years with the easing of the lockdown and trade restrictions.
VALUE CHAIN ANALYSIS
The geographic atrophy (GA) market is anticipated to grow significantly over the forecast period, which can be attributable to factors like an increase in the number of companies who are all moving forward to introduce novel pharmacological molecules for the treatment of geographic atrophy. In addition, the market is expanding as a result of an increase in the demand for research funding for the creation of novel technologies to cure geographic atrophy. The geographic atrophy industry's value chain analysis is divided into four main sections that start with R&D and product creation, go through manufacture, distribution, and post-marketing surveillance.
By Age Group
Adults over the age of 60 have an increased chance of acquiring a number of eye conditions that can impair vision, including geographic atrophy, cataracts, diabetic retinopathy, age-related macular degeneration (AMD), dry eye, glaucoma, and others.
Sharp and central vision are reduced by geographic atrophy, an age-related eye disorder. Additionally, geographic atrophy is becoming more common in people over 75 due to age-related factors. Geographic atrophy, for instance, affects 1.3 percent of people between the ages of 75 and 84, rising to about 22 percent by the age of 90, as per the Retina Study Group of Portugal.
It has been shown that fundus autofluorescence imaging can help in geographic atrophy progression prediction. A diagnostic method for locating fluorophores in the human eye is fundus autofluorescence imaging (FAF). Chemical compounds known as fluorophores glow when they are exposed to the right kind of light. Additionally, fundus autofluorescence, the industry-standard diagnostic imaging technique, is routinely used to visualise the retinal pigment epithelium (RPE) in geographic atrophy.
The microvasculature of the retina and choroid can now be seen using optical coherence tomography angiography (OCT-A), a non-invasive method. Numerous retinal disorders, including geographic atrophy, diabetic retinopathy, vascular occlusions, dry and wet age-related macular degeneration, and others, can be diagnosed and understood with its help.
Local electroretinogram (ERG) responses from many retinal regions can be captured simultaneously using the multifocal electroretinogram (mfERG) approach. Multifocal electroretinography applies light stimulation to the retina in patterns while an electrode records photoreceptor signalling. By varying the light stimulation, the retina is mapped with details on its functionality and sensitivity. Reading ability and contrast sensitivity should be employed to fully measure visual impairment in geographic atrophy.
By Therapeutic Agents Clinical Phase
According to preliminary data from earlier trials, the goal of phase III clinical trials is to confirm that the medication is secure, beneficial, and efficient for the specified indication. To determine whether a novel treatment or drug combination is superior to or equivalent to the present standard of care, phase III clinical trials are used.
If a new medicine is determined to be safe in phase I clinical trials, a phase II clinical trial is done. Numerous clinical research investigates whether recipients of a novel treatment outlive those who do not. Community hospitals or even physician offices may conduct phase II investigations.
Phase I studies are carried out to ascertain the highest dosage of a novel drug that may be supplied safely without producing severe side effects. Even if the drug has been researched in lab and on animals, it is impossible to foresee the adverse effects in people. The best way to deliver the new medicine is also determined by these investigations. Phase I studies also examine how the medicine affects the body and how the body interacts with the drug.
The pre-clinical stage of drug development, sometimes referred to as pre-clinical research or nonclinical investigations, is a phase that takes place before clinical trials involving humans and iterative testing, gathers crucial feasibility, and drug safety data, typically in laboratory animals.
Some of the major key players of Geographic Atrophy (GA) Market are as follows:
AstraZeneca plc, Gyroscope Therapeutics Limited, Hoffmann-La Roche AG, Apellis Pharmaceuticals, Inc., Iveric Bio, Gensight Biologics SA, Stealth BioTherapeutics, Allegro Ophthalmics, LLC, Regenerative Patch Technologies, LLC, Genentech, Inc., Alkeus Pharmaceuticals, Inc., NGM Biopharmaceuticals Inc., Hemera Biosciences LLC, and other players.
By Age Group
Above 60 Years
Above 75 Years
Fundus Autofluorescence (FAF)
Optical Coherence Tomography Angiography (OCT-A)
Multifocal Electroretinography (mfERG)
By Therapeutic Agents Clinical Phase
Late-stage (Phase III)
Pre-clinical stage & Discovery candidates
Geographic atrophy is most prevalent in North America because to rising healthcare spending and the existence of well-known competitors there, such as Iveric Bio, Alkeus Pharmaceuticals Inc., Apellis Pharmaceuticals, Inc., and others. In addition, the growing number of geographic atrophy cases in the area and the growing number of government activities addressing geographic atrophy in the area may help to advance the market position.
Geographic atrophy sales in Europe have been growing at an astounding rate as a result of an ageing population, increased demand for technologically sophisticated treatments, and increased R&D spending in the biopharmaceutical sector. Due to the leading competitors' rapid penetration of industrialized nations like Germany, France, and the UK, the market expansion rate in Europe is fairly large. Improvements in the treatment of GA have been made possible by high-level and active research and development operations in these nations.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|CAGR||CAGR of 7.2% From 2023 to 2030|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Age Group (Above 60 Years, above 75 Years)
• By Diagnosis (Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG))
• By Therapeutic Agents Clinical Phase (Late-stage (Phase III), Phase II, Phase I, Pre-clinical stage & Discovery candidates)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||AstraZeneca plc, Gyroscope Therapeutics Limited, Hoffmann-La Roche AG, Apellis Pharmaceuticals, Inc., Iveric Bio, Gensight Biologics SA, Stealth BioTherapeutics|
|Key Drivers||• Increasing number of seniors.
• Geographic atrophy is becoming more common in every country.
|RESTRAINTS||• Medicines used to treat geographic atrophy are subject to strict government controls.
• Geographic atrophy and other ocular illnesses are not widely known in less developed nations.
Frequently Asked Questions (FAQ) :
Ans. Geographic Atrophy (GA) Market expected grow at a CAGR of 7.2% over the forecast period 2022-2028.
Ans. Geographic atrophy, a severe form of age-related macular degeneration (AMD), causes the macula to continuously deteriorate over time.
Ans. Key drivers of the Geographic Atrophy (GA) Market is the Increasing number of seniors, and Geographic atrophy is becoming more common in every country.
Ans. Above 60 Years, and Above 75 Years are the sub segments of Geographic Atrophy (GA) market.
Ans. The geographic atrophy industry's value chain analysis is divided into four main sections that start with R&D and product creation, go through manufacture, distribution, and post-marketing surveillance.
Table of Content:
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.2 Impact on major economies
126.96.36.199 United Kingdom
188.8.131.52 South Korea
184.108.40.206 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Geographic Atrophy (GA) Market Segmentation, By Age Group
8.1 Above 60 Years
8.2 Above 75 Years
9. Geographic Atrophy (GA) Market Segmentation, By Diagnosis
9.1 Fundus Autofluorescence (FAF)
9.2 Optical Coherence Tomography Angiography (OCT-A)
9.3 Multifocal Electroretinography (mfERG)
10. Geographic Atrophy (GA) Market Segmentation, By Therapeutic Agents
10.1 Clinical Phase
10.2 Late-stage (Phase III)
10.3 Phase II
10.4 Phase I
10.5 pre-clinical stage & Discovery candidates
11. Regional Analysis
11.2 North America
11.3.6 The Netherlands
11.3.7 Rest of Europe
11.4.2 South Korea
11.4.6 Rest of Asia-Pacific
11.5 The Middle East & Africa
11.5.3 South Africa
11.6 Latin America
11.6.3 Rest of Latin America
12.1 AstraZeneca plc
12.1.2 Products/ Services Offered
12.1.3 SWOT Analysis
12.1.4 The SNS view
12.2 Gyroscope Therapeutics Limited
12.3 Hoffmann-La Roche AG
12.4 Apellis Pharmaceuticals, Inc.
12.5 Iveric Bio
12.6 Gensight Biologics SA
12.7 Stealth BioTherapeutics
12.8 Allegro Ophthalmics, LLC
12.9 Regenerative Patch Technologies, LLC
12.10 Genentech, Inc.
13.1 Competitive Benchmark
13.2 Market Share analysis
13.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.